China Emerges as One of the Hotspots for Advanced Drug Development.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c33103) has announced the addition of Drug Development in China: Strategic Challenges & Opportunities to their offering. Globalization globalization Process by which the experience of everyday life, marked by the diffusion of commodities and ideas, is becoming standardized around the world. Factors that have contributed to globalization include increasingly sophisticated communications and transportation of Drug Development: China is the first publication of our recently launched Dynamic Reports on the Globalization of Drug Development. The rapid maturation maturation /mat·u·ra·tion/ (mach-u-ra´shun) 1. the process of becoming mature. 2. attainment of emotional and intellectual maturity. 3. of advanced drug development capabilities in several emerging region hotspots such as China, India, and parts of Eastern Europe Eastern Europe The countries of eastern Europe, especially those that were allied with the USSR in the Warsaw Pact, which was established in 1955 and dissolved in 1991. and South America South America, fourth largest continent (1991 est. pop. 299,150,000), c.6,880,000 sq mi (17,819,000 sq km), the southern of the two continents of the Western Hemisphere. has resulted in strategically significant opportunities for most U.S./EU biopharmaceutical companies to dramatically improve R&D productivity - from big pharma and cash burning biotechs. This initial China focused publication and the periodic updates, supplemental webcasts, proprietary survey data and detailed company profiles which accompany it, provide comprehensive information and in-depth insight on the rapid emergence of advanced drug development capabilities in China (e.g. GLP See gateway location protocol. toxicology toxicology, study of poisons, or toxins, from the standpoint of detection, isolation, identification, and determination of their effects on the human body. Toxicology may be considered the branch of pharmacology devoted to the study of the poisonous effects of drugs. , animal pharmacology pharmacology, study of the changes produced in living animals by chemical substances, especially the actions of drugs, substances used to treat disease. Systematic investigation of the effects of drugs based on animal experimentation and the use of isolated and , clinical trials, risk sharing deals, etc.). It includes a pragmatic assessment of the opportunities this has created for western biopharmaceutical companies, their potential impact on improving drug development productivity, recommendations specific to larger and smaller biopharmaceutical companies, and detailed profiles of companies worth knowing. The staff that wrote and contributed to this report have operating experience in managing collaborations, doing deals, outsourcing (1) Contracting with outside consultants, software houses or service bureaus to perform systems analysis, programming and datacenter operations. Contrast with insourcing. See netsourcing, ASP, SSP and facilities management. to CROs, and managing product development. This Dynamic Report approaches the strategic and practical issues of how to take advantage of the opportunities for improving the economics of product development by increasing or establishing activities in China from the perspective of action oriented o·ri·ent n. 1. Orient The countries of Asia, especially of eastern Asia. 2. a. The luster characteristic of a pearl of high quality. b. A pearl having exceptional luster. 3. operating manager's at large pharmaceutical companies or smaller biotechs. The insights, ideas, data, contacts, and other content provided are based on extensive primary and secondary research, including: --on site visits and interviews with key management at companies in emerging regions discussions with managers in western based companies --ongoing communication with industry leaders in key global hotspots proprietary surveys. For managers who have not yet decided whether to globalize glob·al·ize tr.v. glob·al·ized, glob·al·iz·ing, glob·al·iz·es To make global or worldwide in scope or application. glob their R&D efforts, or who simply want to stay up to date, this service will give you the information you need, in an easy-to-use format. For managers who are in the process of becoming more global, this service is designed to save you time and expense (including the possible expense of missteps). Topics Covered I Executive Summary II Driving Forces in the Globalization of the Biopharmaceutical Industry Introduction Key trends Implications for drug development by western Biopharmaceutical companies III. Situation Analysis and Trends in Global Product Development Survey/Comparative Advantage - Executive Summary Survey and interview detail Regional comparisons IV. In-Depth Country/Regional Profile: China China Overview Executive Summary Pharmaceutical Market Multi National Biopharmaceutical Presence Domestic Product Industry Government policy Regulatory Intellectual Property Capabilities, Companies, and Implications for Western Companies Summary and Methodology Discovery Chemistry Company profiles Clinical Trials Company profiles GLP Toxicology Company profiles GMP GMP (guanosine monophosphate): see guanine. Protein Manufacturing Company profiles Animal Pharmacology Company profiles Risk-Sharing Collaborations Company profiles Summary For more information visit http://www.researchandmarkets.com/reports/c33103 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion